Breaking News, Promotions & Moves

Inceptor Bio Names Matthias Schroff CEO

Schroff has experience developing new medicines in immuno-oncology, inflammatory diseases, and genetic disorders.

Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, appointed Matthias Schroff CEO. Schroff will also join the board of directors. He succeeds Shailesh Maingi, who will remain as executive chairman. Schroff has extensive biopharmaceutical leadership experience with a track record of success building companies and developing new medicines in immuno-oncology, inflammatory diseases, and genetic disorders. Schroff was most recently CEO of Exicure, a publ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters